Core Insights - The article emphasizes the importance of extending healthy life expectancy in the context of an aging population, highlighting the role of gut microbiota in aging and chronic inflammation [1][4]. Company Overview - Guangxi Aisheng Life Technology Co., Ltd. (Aisheng Life) is a national high-tech enterprise focused on longevity research, having established the world's largest longevity human database and microbiome library [1][4]. - The company has published multiple longevity research findings in renowned international journals over its 7+ years of operation, showcasing its influence in the field [1][4]. Recent Research Achievements - Aisheng Life's research team published a paper in the journal Aging Cell, exploring the causal relationships between gut microbes, aging indicators, and age-related diseases, revealing the potential of gut microbiota as biomarkers for health management and disease prevention [4][5]. - The study innovatively integrated gut microbiota, various aging indicators, and numerous age-related diseases into a comprehensive research framework, confirming the significant role of gut microbiota in aging and disease [5][7]. Research Methodology and Findings - The research utilized Mendelian randomization (MR) and linkage disequilibrium score regression (LDSC) to analyze the genetic correlations and causal relationships between gut microbiota and three aging indicators (telomere length, frailty index, and facial aging) as well as 14 age-related diseases (e.g., coronary heart disease, chronic kidney disease, Alzheimer's disease) [5][7]. - Specific gut microbes, such as Bifidobacterium breve, were found to be associated with delayed aging and reduced disease risk, while the enrichment of pathogenic bacteria could increase chronic inflammation and metabolic disorders [5][7]. Predictive Models and Applications - The research team developed predictive models for nine age-related diseases based on identified gut microbes, achieving an average AUC value of 0.832, indicating strong predictive performance [7][10]. - The findings suggest that gut microbiota can causally influence aging indicators by regulating short-chain fatty acid (SCFA) production, improving gut barrier function, and reducing chronic inflammation [7][8]. Future Directions - The study lays a theoretical foundation for developing targeted interventions against aging by modulating gut microbiota, providing new directions for health management, disease early screening, and personalized interventions [8][9]. - Aisheng Life aims to align its development philosophy with national strategies, promoting the application of longevity research outcomes and expanding the global longevity market [8][9]. Innovations and Patents - Aisheng Life has received national invention patent authorization for a probiotic strain (Lactobacillus A21013 and A21033) that has demonstrated efficacy in extending lifespan, reducing fat, enhancing exercise capacity, and improving stress resistance [12]. - The company has also patented another strain (Lactobacillus A21041) with anti-inflammatory and antioxidant properties, which has shown potential in extending lifespan and reducing fat, indicating high practical value for developing longevity products [13][16].

每经记者｜陈星 每经编辑｜魏官红 2025年5月8日晚间，科伦药业（002422.SZ，股价34.14元，市值545.58亿元）董事长刘革新在集团官方视频号发布了一则令不少消费者感到震撼的广告—— 75岁的他赤膊出镜，展示健硕肌肉，为公司旗下抗衰老产品"麦角硫因胶囊"代言。 视频中，刘革新肌肉线条分明，画面配以"刘先生75岁，'没有不可能'"的广告词，迅速在社交媒体引发热议，相关话题一度冲上微博热搜。 据媒体报道，科伦药业证券部工作人员表示，公司董事长一直在吃这款麦角硫因胶囊，视频没有进行后期修饰，董事长长期自律并且每天早上5点会健身。 5月9日，科伦药业方面对《每日经济新闻》记者表示，该产品日本版已经在销售中，公司董事长的确会亲自代言该产品。 对于该条引爆社交网络的广告，科伦药业证券部工作人员对外回应称，刘革新已服用该产品3年，并长期保持严格的健身习惯。公司方面表示，广告视频未 经任何后期修饰，其身材状态完全真实，董事长长期自律并且每天早上5点会健身。 据了解，除了刘革新，科伦药业内部也有员工使用了一段时间这款产品。 这款麦角硫因胶囊由科伦药业全资子公司"科伦永年"销售，在售版本定价1499元/瓶（60粒） ...

智通财经记者 | 唐卓雅 智通财经编辑 | 谢欣 5月8日晚间，科伦集团官方视频号发布了一条麦角硫因胶囊的广告，视频中一男子赤裸上身，展现出结 实的肌肉线条。该视频文案为"刘先生75岁——没有不可能！麦角硫因，生命长青。科伦永年，与您相 伴。" 评论区有人表示："75岁董事长亲自出任大健康产品代言人。"经智通财经记者核实，该视频中出现的男 子确为科伦药业董事长刘革新。公开资料显示，刘革新出生于1951年。1996年，刘革新创办了四川科伦 大药厂——科伦药业的前身，并担任公司董事长至今。 2024年1月发表在《微生物学免疫学进展》的论文《麦角硫因的开发及其在临床医学中的初步应用》一 文指出，麦角硫因是一种天然水性含硫氨基酸，具有强抗氧化能力，主要由微生物合成，在预防和治疗 各种疾病（如心血管疾病、肾脏疾病、糖尿病等）中发挥着重要作用。 不过，前述川宁生物文章最后的截图显示，该麦角硫因的用途是作为生物活性物原料添加到化妆品配方 中使用。记者查询保健品注册信息，并未搜索到有麦角硫因相关产品获批。但是记者拨打科伦药业官方 电话时，工作人员称公司的麦角硫因有口服版也有外用版，都已经经过相关部门批准。 随后，记者以消费者 ...

Core Insights - Japan's medical beauty market has surpassed 600 billion yen (approximately 30.2 billion RMB), exceeding that of South Korea, which is known as a "cosmetic surgery powerhouse" [1][3] - The market is expected to continue growing, driven by advancements in medical technology and changing social attitudes towards cosmetic procedures [3][4] Market Size and Growth - The Japanese medical beauty market was valued at 486 billion yen in 2021, representing a 120% increase from the previous year [3] - In 2023, the market is projected to reach 594 billion yen, marking a growth of 108.8% compared to 2022 [3] - From 2009 to 2023, the market has expanded 2.39 times, indicating robust growth [3] Consumer Behavior and Trends - Approximately 70% of surveyed individuals aged 15 to 49 express concern about their appearance, with 43% considering some form of cosmetic medical treatment [4] - The rise of social media has contributed to a more open attitude towards cosmetic procedures, with many celebrities and influencers openly discussing their experiences [3][4] - Non-surgical treatments, such as laser therapy and hyaluronic acid injections, are particularly popular among consumers [4] Demographic Insights - Male consumers are increasingly participating in cosmetic procedures, with treatments like beard removal gaining popularity for their time-saving benefits [4]

Core Viewpoint - The recent study challenges the belief that NAD+ depletion significantly impacts muscle function and accelerates aging, suggesting that muscle health may not be as dependent on NAD levels as previously thought [2][5][11]. Group 1: Study Findings - The study utilized an inducible skeletal muscle-specific Nampt gene knockout (iSMNKO) mouse model, resulting in an 85% reduction in NAD+ levels without affecting muscle mass, integrity, contraction strength, or exercise performance [2][9]. - Even with lifelong NAD+ depletion, the mice did not exhibit accelerated muscle aging or systemic metabolic impairment [8][9]. - The research indicates that skeletal muscle can tolerate significant NAD+ depletion without losing functionality or accelerating aging, contradicting the common belief that NAD+ reduction is a primary driver of muscle aging and weakness [5][11]. Group 2: Implications for NAD+ Supplementation - The findings raise questions about the efficacy of NAD+ supplementation as an anti-aging strategy, suggesting that it may be a waste of resources [5][11]. - The study's leader emphasized that the results challenge the notion that reduced NAD+ levels are a major factor in muscle aging and weakness [5][11]. - The research highlights the need for further investigation into the extent to which NAD+ reduction affects mitochondrial function and the aging process [6][11].